Healthcare / BiotechnologyKOSDAQ
$38850.00
-4000.00 (-9.33%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 21%
FCF escenarios
weak_data · normalized FCF $-23.5B · quality 59.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
21/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.34T
P/E
N/A
•EV/EBITDA
N/A
•ROE
-24.0%
↓Gross Margin
18.9%
↓Debt/Equity
0.63
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+4.4%
FCF CAGR
—
FCF margin
-276.8%
FCF / Net income
3.25x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $19.32B · net income $-16.45B · FCF $-53.47B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $19.32B | $19.32B | $15.91B | $21.95B | $16.98B |
| Net Income | $-16.45B | $-16.45B | $-10.80B | $-5.60B | $-7.78B |
| EBITDA | $-11.54B | $-11.54B | $-8.60B | $-3.81B | $-6.13B |
| EPS | -601.00 | -601.00 | -542.00 | -323.00 | -460.00 |
| Gross Margin | 18.9% | 18.9% | 17.7% | 25.2% | 18.6% |
| Operating Margin | -63.1% | -63.1% | -57.2% | -19.2% | -30.3% |
| Net Margin | -85.1% | -85.1% | -67.9% | -25.5% | -45.8% |
| Balance Sheet | |||||
| Debt/Equity | 0.63 | 0.63 | 0.76 | 0.16 | 0.22 |
| Current Ratio | 1.72 | 1.72 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-53.47B | $-53.47B | $-23.50B | $-7.92B | $-4.18B |
| Returns | |||||
| ROE | -24.0% | -24.0% | -43.2% | -21.3% | -27.9% |
| Valuation | |||||
| P/B | 15.50 | 15.50 | 4.68 | 1.92 | 2.25 |
| Growth & Yield | |||||
| Revenue Growth | 21.4% | 21.4% | -27.5% | 29.3% | — |
| EPS Growth | -10.9% | -10.9% | -67.8% | 29.8% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+338.5%
Start / end P/E
n/dx → n/dx
EPS bridge
-542.00 → -601.00
Residual
+338.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.